AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01120704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long Term Combination Nicotine Replacement Therapy (patch + gum)
Description: IF the participant smokes >10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 21 mg patch per day for 22 weeks, THEN one 14 mg patch per day for 2 weeks, THEN one patch 7 mg patch per day for 2 weeks. Participants will also be asked to use one piece of one 4-mg- gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment.~IF the participant smokes 5-10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 14 mg patch per day for 22 weeks, THEN one patch 7 mg patch per day for 4 weeks. Participants will also be asked to use one piece of 2-mg gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment.
Study NCT01287390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: video fluoroscopy
Description: video fluoroscopy of swallowing function at baseline, 6 months and 12 months follow-up
Study NCT01287390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extra imaging
Description: For tumor response, 2 extra CT or Fludeoxyglucose (18F)-Positron Emission Tomography (PET)/Computed Tomography (CT), and/or Magnetic Resonance Imaging (MRI) will be performed.
Study NCT01287390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scoring acute toxicity
Description: Acute toxicity scoring, based on Common Toxicity criteria (CTC) version 2.
Study NCT01287390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scoring acute toxicity
Description: Acute toxicity scoring, based on Common Toxicity criteria (CTC) version 2.
Study NCT01287390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scoring of late toxicity
Description: Scoring of late toxicity with the 'late effects in normal tissues subjective, objective, management and analytic'(LENT-SOMA) scale.
Study NCT01287390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scoring of late toxicity
Description: Scoring of late toxicity with the 'late effects in normal tissues subjective, objective, management and analytic'(LENT-SOMA) scale.
Study NCT01287390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scoring quality of life (QOL)
Description: Quality of life is scored with the Quality of Life Questionnaire of the 'European Organisation for Research and Treatment of Cancer' (EORTC QOL-C30) and the Head and Neck Cancer Specific Quality of Life Questionnaire (QLQ-H\&N 35).
Study NCT01287390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scoring quality of life (QOL)
Description: Quality of life is scored with the Quality of Life Questionnaire of the 'European Organisation for Research and Treatment of Cancer' (EORTC QOL-C30) and the Head and Neck Cancer Specific Quality of Life Questionnaire (QLQ-H\&N 35).
Study NCT03709745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection [Eylea]
Description: Intravitreal injection is given as described in the arm description
Study NCT03709745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Injection [Lucentis]
Description: Intravitreal injection is given as described in the arm description
Study NCT01012960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylnaltrexone
Description: 0,15 mg/kg sc ( subcutaneously)once per volunteer
Study NCT01012960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylnaltrexone
Description: 0,15 mg/kg sc ( subcutaneously)once per volunteer
Study NCT02782780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTi)
Description: CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep (e.g., homeostatic regulation, circadian rhythm, age, social and work schedule) and to work with the patients toward minimizing unwanted arousal at bedtime and altering sleep habits to increase sleep propensity and regularity. The intervention is 8-weeks long.
Study NCT03425123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regenerative Endodontic Procedure (REP)
Description: Regenerative Endodontic Procedure (REP) involves disinfection of the root canal with the use of acombination of three antibiotics including ciprofloxacin, metronidazole, minocycline. At the second visit, the patient is evaluated for resolution of signs or symptoms of an acute infection and if none then bleeding is induced, the site covered with a plug and the patient is evaluated at follow up.
Study NCT04023786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP-TEST
Description: The PEEP test will consist of lowering the PEEP level to 5 cmH2O for a maximum of 2 minutes and a minimum of 1 minute. Patients will be included if the physicians who care for them have decided to set a baseline PEEP level ≥10 cmH2O.
Study NCT02835508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 60 Milligram
Description: JNJ-56021927 60 mg oral tablet.
Study NCT02835508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 120 Milligram
Description: JNJ-56021927 120 mg as 2 tablets of 60 mg.
Study NCT02835508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 240 Milligram
Description: JNJ-56021927 240 mg as 4 tablets of 60 mg.
Study NCT04340401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Patients will receive 3 cycles induction CapeOX and SHR-1210
Study NCT04340401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
Study NCT04340401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
Study NCT04340401 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy
Description: patients will receive intensity modulated radiotherapy with capecitabine
Study NCT04340401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision
Description: Patients will receive TME (Total mesorectal excision) following TNT+SHR1210 if no metastasis occurs.
Study NCT04271891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WBPC
Description: The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks.
Study NCT04271891 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Without WBPC
Description: Not treat with WBPC
Study NCT03571269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography-guided reperfusion strategy
Description: Optical coherence tomography will be used to detect the detailed characteristics of culprit lesion and to decide and optimize the reperfusion strategy according to the established algorithm in the protocol.
Study NCT03063554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Ultrasound Guided Biliary Drainage
Description: Endoscopic Ultrasound Guided biliary drainage with stent placement;
Study NCT03063554 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ERCP
Description: Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement
Study NCT01179854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remegal
Description: Drug/ placebo
Study NCT01179854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remegal
Description: Drug/ placebo
Study NCT02521103 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon Tritanium Cone Augments
Description: The Triathlon Tritanium Cone Augments are an extension of the Triathlon Total Stabilizer (TS) system, intended to be used as an optional accessory component in primary or revision TKA
Study NCT03642067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab was administered IV on day 1 of each 28 day cycle.
Study NCT03642067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Relatlimab was administered IV on day 1 of each 28 day cycle.
Study NCT04560673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Given PO
Study NCT01916252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bortezomib (Velcade ®)
Study NCT01120704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Maintenance Counseling
Description: Participants randomized to this condition will receive eight 15-minute phone counseling sessions at Weeks 3, 4, 6, 8, 10, 14, 18 \& 22. The counseling will encourage continued practice of coping skills, and avoidance of danger situations. Another emphasis will be the continued provision of social support as a means of enhancing motivation. Participants who have relapsed will receive counseling aimed at motivating and planning renewed quit attempts. Other aims are enhancing motivation, especially competence self-appraisals, providing intratreatment support, and encouraging pleasurable activities.
Study NCT02818686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473
Study NCT02818686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04560673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Receive neurofeedback training
Study NCT01464489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.~Atropine(atropine sulphate) 10 μg.kg-1, intravenous injection during induction After 120 sec of atropine injection, record intubating condition
Study NCT01464489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1 Normal saline intravenous injection during anesthetic induction After 120 sec of normal saline injection, record intubating condition
Study NCT02208557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reinforcement with Absorbable Mesh
Study NCT04560673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02208557 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Control CT
Description: At the end of the follow up (6 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the linea alba seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for midline fascial closure.
Study NCT02208557 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Control CT
Description: At the end of the follow up (6 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the linea alba seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for midline fascial closure.
Study NCT02208557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Follow Up
Description: The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
Study NCT02208557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Follow Up
Description: The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
Study NCT04560673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05367414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy massage (diluted tea tree oil)
Description: massage with diluted tea tree oil was applied
Study NCT05367414 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: aromatherapy massage (sweet almond oil)
Description: massage with sweet almond oil was applied
Study NCT03729804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be given by IV on Days 1, 2, 15 and 16 of each cycle during cycles 1-8.~Carfilzomib will be given by IV on days 1, 2, 15 and 16 of each cycle during cycles 9-24.
Study NCT03729804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle during cycles 1-8.~Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle for cycles 9-24.
Study NCT03729804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be taken by mouth on days 1, 8, 15 and 22 of each cycle during cycles 1-8.~Dexamethasone will be taken by mouth on Days 1, 8, 15 and 22 of each cycle during cycles 9-24.
Study NCT03729804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be give by IV on days 1, 4, 8 and 11 of each cycle during cycles 1-8.
Study NCT04561232 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Prone and Upright Locomotor Training
Description: During the movement observation phase, infants will wear a wireless movement sensor at each ankle for two days. Research staff will show the caregivers how to place the sensors in the morning and charge them overnight.~The training protocol for the prone training will consist of: 1) Warm-up. 2) Assisted movement of the arms and legs. 3) Calibration of the infant's arm and leg positions. 4) Self-initiated mobility for up to five minutes.~For upright training, the environment will be arranged to encourage active motor exploration and variability in walking activities.The therapist will assist the child as needed to encourage upright locomotor activities, but only the minimum amount needed to perform the task. Weight assistance will be gradually reduced as postural control and coordination improve.
Study NCT04671446 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Autoantibody ELISA
Description: Serum will be tested for novel autoantibodies against candidate auto-antigens by ELISA, such as those previously identified as of importance (e.g. eosinophil peroxidase, EPX) and also novel candidate proteins specific to eosinophils as identified by FANTOM5 geneset analysis.
Study NCT01916252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenalidomide (Revlimid®)
Study NCT01916252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: busulfan (Busilvex ®)
Study NCT01916252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone acetate
Study NCT01916252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Study NCT06607601 — intervention group
Intervention type: DRUG
Intervention: Palbociclib
Description: Treatment information in the electronic health record indicates initiation of palbociclib after metastatic diagnosis
Study NCT06607601 — intervention group
Intervention type: DRUG
Intervention: Letrozole
Description: Treatment information in the electronic health record indicates initiation of letrozole after metastatic diagnosis
Study NCT00855933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Floss
Description: Experimental Glide® floss with cetylpyridinium chloride (\~13% dry weight CPC)
Study NCT00937742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tomato products
Description: Specified amounts of tomato products (i.e. tomato juice, ketchup, salsa, tomato soup, spaghetti sauce) to be consumed daily during a 6 week intervention phase.
Study NCT00003783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT01120704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Medication Adherence Counseling (CAM)
Description: Participants randomized to this condition will be given a brief (10 minute) session of CAM treatment at both Visits 1 and 2. CAM will include information on NRT such as the following: NRT reduces withdrawal and urges; sustained use reduces the likelihood of relapse; willpower and medication make a good combination; NRT will help a lapsing smoker reachieve abstinence. The tailored counseling component of the CAM intervention is based on brief evaluation of the smoker's beliefs, concerns, and possible misconceptions about smoking cessation medications.
Study NCT01120704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Medication Monitoring Device (the Helping Hand) + Feedback
Description: If randomized to this condition, the case manager will give patients a computer-generated feedback sheet showing the patient's medication self-administration since the last visit. The case manager will provide problem-solving counseling regarding barriers to medication use. This problem-solving counseling intervention will be given in brief in-person sessions (three in-person sessions for those in the 8 week medication condition and five in-person sessions for those in the 26 week medication condition). Medication monitoring counseling will also occur via phone (two 10-minute sessions for those in the 8 week medication condition and four 10-minute sessions for those in the 26 week medication condition).
Study NCT04671446 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Granulocyte Immunofluorescence
Description: The presence of auto-antibodies in patient serum to inactive and activated neutrophils / eosinophils, with and without post-translational modification, will be examined by indirect immunofluorescence.
Study NCT01120704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Adherence Prompting Phone Calls
Description: Participants in this condition will receive fully automated prompts with messages designed to encourage participants to take their medication.~Adherence prompting calls will occur two times in the first week of the quit attempt, and then once a week in weeks 2, 3, 4, 5, and 7. Those in the 26-Week medication condition who are assigned to the active adherence prompting calls intervention, will receive one prompting call a week during Weeks 11, 15, 19 \& 23.
Study NCT00003783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Study NCT00003783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00003783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00003783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Study NCT00003783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT01874769 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: * 5 ml of blood on dry tube: Verification of the absence of auto-antibodies to type VII collagen.~* 10 ml of blood sample on heparin: Verification of the absence of circulating reactive T-Lymphocytes clones to type VII collagen~* 5 ml of Blood samples on ethylenediaminetetraacetic acid (EDTA): HLA genotyping of patient selected on the clinical and molecular criteria.
Study NCT01874769 — intervention group
Intervention type: OTHER
Intervention: Skin biopsies
Description: * A 5-mm punch skin biopsy in the groin region performed under local anaesthesic will be undertaken during visit 1.~* During the second visit, two additional 5-mm punch skin biopsies will be taken to assess stem cells proliferative capacity in 10 shortlisted patients
Study NCT00003783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT03354611 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Cone Beam Breast CT Scan
Description: * Pre-contrast scan~* Begin contrast injection (and saline chaser)~* Post-contrast Scan. Start time of post-contrast CE-CBBCT scan is 90-200 seconds after start of injection, depending on method of contrast delivery (bolus vs hand injection)
Study NCT03354611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast Dye, Iodinated
Description: 1.5-2ml/kg body weight (100 ml maximum) of a low osmolar, nonionic, 300-350 mgI/ml iodinated contrast agent, will be injected at a rate of \~2.0 ml/s, for a total injection time of 30-60 seconds (for a 50 kg subject). This will be immediately followed by a saline chaser from 20 to 40 ml at \~2 ml/s (20 seconds) to maximize dynamic enhancement.
Study NCT00003783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin